Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio's board has approved plans to explore separating its business into two independent, publicly traded companies. The company says the separation is expected to occur by the end of 2026. Management will host a conference call using a slide presentation to discuss the potential separation; the presentation is included as an exhibit. A press release describing the board action is also attached as an exhibit. The disclosure notes that the Item 7.01 information and the presentation are not deemed "filed" for Section 18 purposes.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,426,893 shares of AnaptysBio, Inc. (ANAB), representing 5.1% of the outstanding common stock. The Schedule 13G discloses shared voting and dispositive power over these shares with no sole voting or dispositive power reported. The filing indicates the securities are held by entities subject to voting control and investment discretion by Millennium and related managers.
The filing includes a Joint Filing Agreement dated September 22, 2025, and certifications that the holdings were not acquired to change or influence control of the issuer. Addresses for the reporting persons and CUSIP 032724106 are provided.
ANAPTYSBIO, Inc. (ANAB) director John A. Orwin received a grant of 1,300 restricted stock units (RSUs) reported on Form 4 with a transaction date of 09/15/2025. Each RSU represents a contingent right to one share of common stock to be settled for no consideration. The filing shows 10,665 shares beneficially owned by Mr. Orwin following the reported transaction. The RSUs are subject to a time-based vesting schedule stated in the filing: one‑third vested on 09/15/2024, one‑third on 09/15/2025 and the final one‑third on 09/15/2026, each tranche conditioned on continued service. The Form 4 was signed by an attorney‑in‑fact on 09/17/2025.
Renton Hollings, a director of AnaptysBio (ANAB), exercised options and sold shares under a Rule 10b5-1 plan. On 08/08/2025 he exercised options with an exercise price of $6.93 to acquire 10,231 shares and sold portions of those shares: 3,110 sold at a weighted-average price of $19.44 (sales ranged $19.375–$19.46) and 7,121 sold at a weighted-average price of $19.696 (sales ranged $19.48–$20.46). The sales were effected pursuant to a 10b5-1 trading plan adopted March 14, 2024.
Additional details: the exercised options include a 2015 grant that is fully vested and exercisable through its expiration on August 13, 2025. The filing notes remaining options to purchase 10,231 shares referenced in Table II and additional options to purchase up to an aggregate of 101,820 shares. The Form 4 was filed with a signature dated 08/12/2025 by an attorney-in-fact.
AnaptysBio, Inc. (ANAB) Form 144 shows an intended sale of 10,231 common shares with an aggregate market value of $200,712.78 to be executed on or about 08/08/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing states these shares were acquired by a stock option exercise on 08/08/2025 with payment in cash. The notice also discloses prior sales by the same person, HOLLINGS C RENTON: 20,925 shares sold 07/02/2025 for $493,189.70 and 3,015 shares sold 06/18/2025 for $72,269.55. The signer represents there is no undisclosed material adverse information.
AnaptysBio is registering 1,650,000 additional shares of its common stock to be available under the Amended and Restated 2017 Equity Incentive Plan following stockholder approval. The filing makes those shares available for future awards to employees and directors and incorporates prior S-8 registrations and related company filings on file with the SEC.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.
The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.